Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

This publication has 38 references indexed in Scilit:

• Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19
  JAMA, 2023
• Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
  JAMA, 2022
• Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis
  JAMA Network Open, 2022
• Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results
  Journal of Clinical Epidemiology, 2021
• Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)
  eClinicalMedicine, 2021
• Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis
  Journal of General Internal Medicine, 2021
• Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
  The Lancet, 2021
• The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
  Antiviral Research, 2020
• Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice
  Inflammation Research, 2008
• Pragmatic clinical trials
  Complementary Therapies in Medicine, 2004